Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome.
Journal
Cancer discovery
ISSN: 2159-8290
Titre abrégé: Cancer Discov
Pays: United States
ID NLM: 101561693
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
15
06
2020
revised:
14
12
2020
accepted:
11
03
2021
pubmed:
18
3
2021
medline:
26
2
2022
entrez:
17
3
2021
Statut:
ppublish
Résumé
Immunotherapies targeting aspects of T cell functionality are efficacious in many solid tumors, but pancreatic ductal adenocarcinoma (PDAC) remains refractory to these treatments. Deeper understanding of the PDAC immune ecosystem is needed to identify additional therapeutic targets and predictive biomarkers for therapeutic response and resistance monitoring. To address these needs, we quantitatively evaluated leukocyte contexture in 135 human PDACs at single-cell resolution by profiling density and spatial distribution of myeloid and lymphoid cells within histopathologically defined regions of surgical resections from treatment-naive and presurgically (neoadjuvant)-treated patients and biopsy specimens from metastatic PDAC. Resultant data establish an immune atlas of PDAC heterogeneity, identify leukocyte features correlating with clinical outcomes, and, through an
Identifiants
pubmed: 33727309
pii: 2159-8290.CD-20-0841
doi: 10.1158/2159-8290.CD-20-0841
pmc: PMC8338775
mid: NIHMS1686435
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2014-2031Subventions
Organisme : NICHD NIH HHS
ID : R21 HD099367
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA224012
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA210171
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA247886
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA223150
Pays : United States
Organisme : NCI NIH HHS
ID : U2C CA233280
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA209988
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA197296
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA226909
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA196228
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002369
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA231877
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA186241
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA127003
Pays : United States
Informations de copyright
©2021 American Association for Cancer Research.
Références
Cancers (Basel). 2020 Feb 29;12(3):
pubmed: 32121328
Nature. 2020 Jan;577(7791):556-560
pubmed: 31942077
Cells. 2020 Jun 01;9(6):
pubmed: 32492969
Nat Immunol. 2004 Feb;5(2):141-9
pubmed: 14704792
Cancer Immunol Res. 2014 Jul;2(7):616-31
pubmed: 24942756
Immunity. 2020 May 19;52(5):825-841.e8
pubmed: 32396847
Sci Rep. 2019 Oct 10;9(1):14602
pubmed: 31601875
Cell Rep. 2017 Apr 4;19(1):203-217
pubmed: 28380359
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
J Immunother Cancer. 2018 Jun 6;6(1):48
pubmed: 29871672
Elife. 2018 Sep 04;7:
pubmed: 30179157
Proc Natl Acad Sci U S A. 2019 Jan 29;116(5):1692-1697
pubmed: 30635425
Nat Rev Cancer. 2019 Jun;19(6):307-325
pubmed: 31092904
Elife. 2018 Jul 11;7:
pubmed: 29993362
Annu Rev Immunol. 2019 Apr 26;37:457-495
pubmed: 30676822
Lancet. 2018 May 26;391(10135):2128-2139
pubmed: 29754777
Trends Cancer. 2018 Jun;4(6):418-428
pubmed: 29860986
Nat Commun. 2017 Apr 27;8:15095
pubmed: 28447602
Methods Enzymol. 2020;635:1-20
pubmed: 32122539
Nature. 2020 Jan;577(7791):549-555
pubmed: 31942075
Cancer J. 2017 Nov/Dec;23(6):343-349
pubmed: 29189330
Cancer Immunol Res. 2017 Nov;5(11):978-991
pubmed: 29066497
Gut. 2012 Jul;61(7):1085-94
pubmed: 21749982
Nature. 2017 Nov 23;551(7681):512-516
pubmed: 29132146
N Engl J Med. 2011 May 12;364(19):1817-25
pubmed: 21561347
Clin Cancer Res. 2020 Jul 15;26(14):3578-3588
pubmed: 32273276
Cancer Discov. 2011 Jun;1(1):54-67
pubmed: 22039576
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Nat Med. 2018 May;24(5):541-550
pubmed: 29686425
Mod Pathol. 2019 Oct;32(10):1495-1507
pubmed: 31186528
Cancer Cell. 2018 Apr 9;33(4):563-569
pubmed: 29634944
Br J Cancer. 2019 Jul;121(1):5-14
pubmed: 31110329
Nature. 2020 Jan;577(7791):561-565
pubmed: 31942071
Nat Rev Cancer. 2012 Mar 15;12(4):298-306
pubmed: 22419253
Nat Rev Immunol. 2015 Aug;15(8):486-99
pubmed: 26205583
Cell. 2018 Sep 6;174(6):1373-1387.e19
pubmed: 30193111
Nat Cancer. 2020 Nov;1(11):1097-1112
pubmed: 34296197
Nat Rev Immunol. 2019 Nov;19(11):665-674
pubmed: 31570879
Br J Cancer. 2013 Mar 5;108(4):914-23
pubmed: 23385730
Nat Rev Clin Oncol. 2015 Jun;12(6):319-34
pubmed: 25824606
N Engl J Med. 2018 Dec 20;379(25):2395-2406
pubmed: 30575490
Immunity. 1998 Sep;9(3):325-36
pubmed: 9768752
Clin Cancer Res. 2021 Feb 15;27(4):1069-1081
pubmed: 33262135
Oncoimmunology. 2012 Sep 1;1(6):829-839
pubmed: 23162750
Nat Rev Immunol. 2019 Jun;19(6):369-382
pubmed: 30718830
Br J Cancer. 2015 May 26;112(11):1782-90
pubmed: 25942397